PubRank

Falk Hiepe

Author PubWeight™ 73.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006 5.22
2 Maintenance of serum antibody levels. Annu Rev Immunol 2005 3.20
3 Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2004 3.17
4 Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004 2.85
5 Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2008 2.59
6 Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol 2012 2.12
7 Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008 2.00
8 Memory B and memory plasma cells. Immunol Rev 2010 1.95
9 Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2008 1.91
10 Plasma cell differentiation and survival. Curr Opin Immunol 2008 1.71
11 Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002 1.63
12 Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 1.62
13 Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012 1.59
14 Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008 1.53
15 Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005 1.51
16 Adaptation of humoral memory. Immunol Rev 2006 1.29
17 Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004 1.24
18 Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 2012 1.18
19 Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011 1.17
20 Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2011 1.15
21 Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. J Autoimmun 2012 1.13
22 Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 2013 1.13
23 CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol 2004 1.08
24 Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 2005 1.05
25 Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011 1.05
26 Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2009 1.04
27 Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 2009 1.04
28 Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 2012 1.03
29 Risks of immune system treatments. Science 2010 1.00
30 IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2012 0.99
31 Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009 0.98
32 Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 2011 0.96
33 Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol 2008 0.96
34 Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur J Immunol 2010 0.94
35 The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) 2012 0.93
36 International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006 0.93
37 Long-lived plasma cells in immunity and immunopathology. Immunol Lett 2005 0.92
38 Casein is an essential cofactor in autoantibody reactivity directed against the C-terminal SmD1 peptide AA 83-119 in systemic lupus erythematosus. Immunobiology 2002 0.87
39 Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis 2013 0.86
40 Selection and depletion of plasma cells based on the specificity of the secreted antibody. Eur J Immunol 2014 0.85
41 Simultaneous cytometric analysis of (auto)antigen-reactive T and B cell proliferation. Immunobiology 2002 0.85
42 Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009 0.84
43 Phenotypic analysis of B-cells and plasma cells. Methods Mol Med 2007 0.83
44 Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010 0.83
45 The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med 2014 0.83
46 Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J Immunol 2004 0.83
47 The role of long-lived plasma cells in autoimmunity. Immunobiology 2002 0.82
48 Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum 2003 0.82
49 Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics 2002 0.81
50 Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010 0.81
51 Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease? Immunogenetics 2010 0.79
52 Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. Arthritis Res Ther 2014 0.78
53 Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis and secondary Sjögren's syndrome. J Rheumatol 2002 0.78
54 Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis. Arthritis Res Ther 2009 0.78
55 Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients. J Neuroimmunol 2013 0.77
56 A case of Erdheim-Chester disease initially mistaken for Ormond's disease. Nat Clin Pract Rheumatol 2008 0.76
57 The intracellular 52-kd Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I. Arthritis Rheum 2005 0.76
58 Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study. Arthritis Res Ther 2011 0.75
59 Lupus nephritis: Transatlantic management recommendations compared. Nat Rev Rheumatol 2012 0.75
60 Developments in lupus 2006. Arthritis Res Ther 2007 0.75
61 Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther 2011 0.75
62 Severe disease activity and complications of immunosuppressive therapy: a challenge for acute hospital-based rehabilitation in rheumatology. J Rheumatol 2009 0.75
63 Development and resolution of secondary autoimmunity after autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: competition of plasma cells for survival niches? Ann Rheum Dis 2013 0.75